BiotechTube

AN0025

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Esophageal Cancer

Conditions

Esophageal Cancer

Trial Timeline

Jan 18, 2022 → Dec 1, 2025

NCT ID
NCT05191667

About AN0025

AN0025 is a phase 1 stage product being developed by Adlai Nortye for Esophageal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05191667. Target conditions include Esophageal Cancer.

What happened to similar drugs?

19 of 20 similar drugs in Esophageal Cancer were approved

Approved (19) Terminated (2) Active (1)
✅rabeprazole and pantoprazoleEisaiApproved
✅rabeprazole + pantoprazoleEisaiApproved
✅Placebo + CisaprideJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05358691Phase 1Withdrawn
NCT05191667Phase 1Active

Competing Products

20 competing products in Esophageal Cancer

See all competitors
ProductCompanyStageHype Score
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
39
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
39
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
47
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
39
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPhase 1
29
FamotidineAstellas PharmaPhase 2/3
38
ASP546CAstellas PharmaPhase 1/2
39
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
JS001 + nab-paclitaxel + Cisplatin + CarboplatinSun PharmaceuticalPhase 2
42
E3810 + E3810 + PlaceboEisaiPhase 3
40